Veru (NASDAQ:VERU) Now Covered by Analysts at Canaccord Genuity Group

Investment analysts at Canaccord Genuity Group started coverage on shares of Veru (NASDAQ:VERU) in a research report issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $25.00 price target on the stock.

A number of other research analysts have also recently issued reports on the company. Oppenheimer reissued an “outperform” rating on shares of Veru in a report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.00.

Veru Stock Down 8.6%

Shares of VERU opened at $2.23 on Thursday. The stock has a market cap of $32.69 million, a price-to-earnings ratio of -1.01 and a beta of -1.01. Veru has a 12 month low of $2.11 and a 12 month high of $14.20. The company has a 50-day moving average price of $2.96 and a two-hundred day moving average price of $4.12.

Hedge Funds Weigh In On Veru

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in Veru by 5.5% during the 2nd quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock worth $108,000 after purchasing an additional 9,637 shares during the period. Northwestern Mutual Wealth Management Co. bought a new position in shares of Veru during the 3rd quarter worth $38,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Veru during the third quarter valued at $47,000. 180 Wealth Advisors LLC raised its holdings in shares of Veru by 5.9% in the second quarter. 180 Wealth Advisors LLC now owns 458,887 shares of the company’s stock valued at $267,000 after acquiring an additional 25,554 shares in the last quarter. Finally, SeaCrest Wealth Management LLC raised its holdings in shares of Veru by 19.6% in the second quarter. SeaCrest Wealth Management LLC now owns 165,000 shares of the company’s stock valued at $96,000 after acquiring an additional 27,000 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.